| Date Filed | Type | Description |
| 08/14/2023 |
SC 13D/A
| INCYTE CORP reports a 6.9% stake in Merus n.v. |
| 08/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 4.6% stake in MERUS, N.V. |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 5.9% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 0% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.4% stake in Merus N.V. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 5.1% stake in Merus N.V. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 8.5% stake in MERUS, N.V. |
| 01/09/2023 |
8-K
| Investor presentation |
| 01/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/30/2022 |
SC 13G
| Flynn James E reports a 5.5% stake in Merus N.V. |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
SC 13G
| COMMODORE CAPITAL LP reports a 5.1% stake in Merus N.V. |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| Boxer Capital, LLC reports a 4.4% stake in Merus N.V. |
| 02/14/2022 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 8.5% stake in MERUS, N.V. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/25/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145 UTRECHT, The Netherlands and CAMBRIDGE, Mass., January 25, 2022 — Merus N.V. , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. “Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical program, zenocutuzumab for neuregulin 1 fusion cancer and developing our commercial approach for our pip..." |
|
|